Monitoring Schistosome Hybrids Under Under Praziquantel Pressure

• Register: ClinicalTrials.gov
• Last refreshed on: 12 December 2020
• Main ID: NCT04635553
• Date of registration: 13/11/2020
• Prospective Registration: Yes
• Primary sponsor: Institut de Recherche pour le Developpement
• Public title: Monitoring Schistosome Hybrids Under Under Praziquantel Pressure Sen_hybrids
• Scientific title: Prevalence of Potential Schistosome Hybrids and Their Invasive Capacity Under Praziquantel Pressure in Northern Senegal
• Date of first enrolment: August 11, 2020
• Target sample size: 250
• Recruitment status: Recruiting
• URL: https://clinicaltrials.gov/show/NCT04635553
• Study type: Observational

Countries of recruitment

Senegal

Contacts

• Name: Bruno SENGHOR, PhD

Key inclusion & exclusion criteria

Inclusion Criteria:

- Children between the initiation courses (CI) and elementary course second year (CE2)

- Absence of declared chronic pathologies that could impact the follow-up

- Be positive for S. haematobium infection during the selection period (excreting eggs)

- Residing in the study area during the 3 years of the follow-up

Exclusion Criteria:

- Absence of written informed consent or expressed refusal from the child

- Enrolled in another on going study, which implicates the administration of PZQ or
tests another product.



Age minimum: 5 Years
Age maximum: 10 Years
Gender: All

Health Condition(s) or Problem(s) studied

Schistosomiasis

Intervention(s)

Drug: Praziquantel 600 milligram

Primary Outcome(s)

Change from baseline in prevalence and intensity of schistosome infection [Time Frame: December 31. 2020]

Secondary Outcome(s)

Hybrids tolerance to praziquantel [Time Frame: December 31, 2021]

Secondary ID(s)

SEN2020-BS

Source(s) of Monetary Support

Please refer to primary and secondary sponsors